Recent Achievement Deals
Recent achievements in alliance activities are presented below.
Our partners are variety of global or domestic pharmaceutical companies or biotech companies. We flexibly arrange role assignments with our partners on research, development and sales territories under discussions based on mutual trust. Marked (*) items are under responsibility of Millennium: The Takeda Oncology Company.
| Licensor | Product Name or Development Code | Drug Class | Indication(s) | Territory | Time |
| Orexigen Therapeutics |
Contrave® |
Obesity |
US, Canada and Mexico |
Sep.10 |
|
| AMAG |
Feraheme® |
Iron-deficiency anemia |
EU, Canada, Turkey, CIS, Asia (except Japan, China, and Taiwan) |
Mar.10 |
|
| Seattle Genetics* |
SGN-35 |
Hodgkin's lymphoma Systemic anaplastic large-cell lymphoma |
Worldwide (except US and Canada) |
Dec.09 |
|
| Amylin |
AC137-164594 |
Obesity |
Worldwide |
Oct.09 |
|
| Novartis |
TAK-816 |
Haemophilus influenzae type B (Hib) vaccine |
Hib infection prophylaxis |
Japan (Hib vaccine) Worldwide (combined vaccines using Hib vaccine) |
May.09 |
| Japan Poliomyelitis Research |
Seed viruses for the Sabin-inactivated poliovirus vaccine |
Polio prophylaxis |
Worldwide |
Mar.08 |
|
| Amgen |
Vectibix™ AMG706 etc. |
Cancer etc. |
Japan (Vectibix™ etc.), Worldwide (AMG706) |
Feb.08 |
|
| Lundbeck |
Lu AA21004 Lu AA24530 |
Major depression and generalized anxiety disorder |
Japan |
Nov.07 |
|
| US |
Sep.07 |
||||
| Santhera |
Sovrima |
Duchenne Muscular Dystrophy |
EU |
Aug.07 |
|
| Friedreich's Ataxia |
US and EU |
Aug.05 |
|||
| Xenon |
XEN-401 |
Neuropathy and inflammatory pain |
Japan and Asia |
Sep.06 |
|
| Galaxy Biotech |
TAK-701 (HuL2G7) |
Anti-HGF humanized antibody |
Cancer |
Worldwide |
Jul. 06 |
| Affymax |
Hematide™/ Peginesatide |
Erythropoiesis - stimulating agent |
Anemia of chronic kidney disease (CKD) and cancer |
Worldwide except Japan |
Jun.06 |
| Japan |
Feb.06 |
||||
| Pronova Biocare AS |
TAK-085 |
EPA/DHA |
Hypertriglyceridemia |
Japan |
Nov.05 |
| Sucampo Pharmaceuticals |
AMITZA |
Chloride channel opener |
Chronic idiopathic constipation Constipation - predominant Irritable Bowel Syndrome |
US and Canada |
Oct.04 |
| Norgine BV (Oct. 2009, Alizyme transferred ATL-962 business to Norgine BV) |
ATL-962 |
Lipase inhibitor |
Obesity, diabetes |
Japan |
Jan.04 |
| Andrx |
Combination product of Actos and metformin extended release |
Diabetes |
Worldwide |
Jan.04 |
|
| Ajinomoto |
Benet |
Bone resorption inhibitor |
Osteoporosis |
Japan |
May.02 |
| Licensor | Agreement | Indication(s) or Classification | Time |
| Janssen |
Co-promotion of bortezomib (VELCADE) in Japan. |
Multiple Myeloma |
May.10 |
| Janssen |
Co-marketing of galantamine in Japan |
Alzheimer’s disease |
Mar.10 |
| Pfizer |
Co-promotion of pioglitazone (Actos) in China |
Diabetes |
Dec.09 |
| Wyeth/Wyeth Japan |
Co-promotion of etanercept (Enbrel) in Japan |
Rheumatoid arthritis |
May.03 |
| Kissei Pharmaceutical |
Co-marketing of short-acting postprandial hyperglycemia suppressant (Glufast) in Japan |
Antihyperglycemic |
Aug.02 |